GlassScriptPhysician profile
John Woytanowski
NPI 1467802835
$7,182.02
in general payments reported to CMS, 2019-2025
16 companies · $4,332 in 2025
The $4,332 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $203 · 2021: $231 · 2022: $321 · 2023: $1,305 · 2024: $230 · 2025: $4,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,000 · Travel and Lodging: $995 · Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,000.00 |
| Travel and Lodging | $995.40 |
| Food and Beverage | $871.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,264.43 | 2023-2025 | Da Vinci Surgical System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $411.49 | 2020-2024 | Ofev |
| Astrazeneca Pharmaceuticals LP | $355.80 | 2019-2024 | Tezspire |
| Glaxosmithkline, LLC. | $335.33 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $214.70 | 2019-2024 | Uptravi, Opsumit |
| Insmed, INC. | $129.57 | 2019 | |
| Amgen INC. | $122.66 | 2023 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $109.00 | 2022 | |
| United Therapeutics Corporation | $55.26 | 2020-2021 | |
| Boston Scientific Corporation | $39.79 | 2020-2021 | |
| Pulmonx Corporation | $34.93 | 2021-2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Novartis Pharmaceuticals Corporation | $29.93 | 2019 | |
| Erbe USA INC | $25.00 | 2020-2024 | |
| Mylan Specialty L.P. | $20.00 | 2022 | |
| Ambu INC. | $19.78 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pinnacle Biologics, INC | $14.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Woytanowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.